Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis

Journal of Cellular Biochemistry

Volumn 115, Issue 2, 2014, Pages 349-358

  Bian, Zhouyan ^a,b   Dai, Jia ^a,b   Hiroyasu, Nakano ^c,d   Guan, Hongjing ^a   Yuan, Yuan ^a   Gan, Lihua ^b   Zhou, Heng ^a,b   Zong, Jing ^a,b   Zhang, Yan ^a   Li, Fangfang ^a,b   Yan, Ling ^a   Shen, Difei ^a   Li, Hongliang ^a,b   Tang, Qizhu ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c JUNTENDO UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cardiac Hypertrophy; Fibrosis; TRAF5

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; GENE DISRUPTION; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TRANSTHORACIC AORTA CONSTRICTION; ULTRASOUND TRANSDUCER; WILD TYPE;

CARDIAC HYPERTROPHY; FIBROSIS; TRAF5;

ANIMALS; AORTA; CARDIOMEGALY; CONSTRICTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 5;

EID: 84890471780     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24669     Document Type: Article

References (41)

1. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, Morimoto C, Ware CF, Malinin NL, Wallach D, Yagita H, Okumura K,. 1998. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem 273: 13353-13358.
2. Berk BC, Fujiwara K, Lehoux S,. 2007. ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575.
3. Bian Z, Cai J, Shen DF, Chen L, Yan L, Tang Q, Li H,. 2009. Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis. J Cell Mol Med 13: 1302-1313.
4. Bian ZY, Huang H, Jiang H, Shen DF, Yan L, Zhu LH, Wang L, Cao F, Liu C, Tang QZ, Li H,. 2010. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension 55: 257-263.
5. Bian ZY, Wei X, Deng S, Tang QZ, Feng J, Zhang Y, Liu C, Jiang DS, Yan L, Zhang LF, Chen M, Fassett J, Chen Y, He YW, Yang Q, Liu PP, Li H,. 2012. Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) 90: 895-910.
6. Cai J, Yi FF, Bian ZY, Shen DF, Yang L, Yan L, Tang QZ, Yang XC, Li H,. 2009. Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 13: 909-925.
7. Dai J, Shen DF, Bian ZY, Zhou H, Gan HW, Zong J, Deng W, Yuan Y, Li F, Wu QQ, Gao L, Zhang R, Ma ZG, Li HL, Tang QZ,. 2013. IKKi deficiency promotes pressure overload-induced cardiac hypertrophy and fibrosis. PLoS ONE 8: e53412.
8. Das S, Otani H, Maulik N, Das DK,. 2006. Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol 41: 248-24855.
9. Dorn GW, II., 2007. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49: 962-970.
10. Dorn GW, II., Robbins J, Sugden PH,. 2003. Phenotyping hypertrophy: Eschew obfuscation. Circ Res 92: 1171-1175.
11. Gupta S, Das B, Sen S,. 2007. Cardiac hypertrophy: Mechanisms and therapeutic opportunities. Antioxid Redox Signal 9: 623-652.
12. Ishida TK, Tojo T, Aoki T, Kobayashi N, Ohishi T, Watanabe T, Yamamoto T, Inoue J,. 1996. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 93: 9437-9442.
13. Kehat I, Molkentin JD,. 2010. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann NY Acad Sci 1188: 96-102.
14. Kraus ZJ, Nakano H, Bishop GA,. 2009. TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40. Proc Natl Acad Sci USA 106: 17140-17145.
15. Kumarapeli AR, Su H, Huang W, Tang M, Zheng H, Horak KM, Li M, Wang X,. 2008. Alpha B-crystallin suppresses pressure overload cardiac hypertrophy. Circ Res 103: 1473-1482.
16. Leask A,. 2007. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 74: 207-212.
17. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, Li C,. 2004. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287: H1712-H1720.
18. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP,. 2007a. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 49: 1399-1408.
19. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC,. 2007b. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115: 1885-1894.
20. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, Bai X, Zhou H, Jiang H, Heximer SP, Qin M, Huang H, Liu PP, Huang C,. 2010. Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci USA 107: 13818-13823.
21. Liehn EA, Zernecke A, Postea O, Weber C,. 2006. Chemokines: Inflammatory mediators of atherosclerosis. Arch Physiol Biochem 112: 229-238.
22. Malinin NL, Boldin MP, Kovalenko AV, Wallach D,. 1997. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385: 540-544.
23. Missiou A, Rudolf P, Stachon P, Wolf D, Varo N, Aichele P, Colberg C, Hoppe N, Ernst S, Munkel C, Walter C, Sommer B, Hilgendorf I, Nakano H, Bode C, Zirlik A,. 2010. TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res 107: 757-766.
24. Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J,. 1998. Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5). Gene 207: 135-140.
25. Nakano H, Oshima H, Chung W, Williams-Abbott L, Ware CF, Yagita H, Okumura K,. 1996. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem 271: 14661-14664.
26. Nakano H, Shindo M, Yamada K, Yoshida MC, Santee SM, Ware CF, Jenkins NA, Gilbert DJ, Yagita H, Copeland NC, Okumura K,. 1997. Human TNF receptor-associated factor 5 (TRAF5): cDNA cloning, expression and assignment of the TRAF5 gene to chromosome 1q32. Genomics 42: 26-32.
27. Nakano H, Sakon S, Koseki H, Takemori T, Tada K, Matsumoto M, Munechika E, Sakai T, Shirasawa T, Akiba H, Kobata T, Santee SM, Ware CF, Rennert PD, Taniguchi M, Yagita H, Okumura K,. 1999. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci USA 96: 9803-9808.
28. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K,. 1999. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
29. Oceandy D, Pickard A, Prehar S, Zi M, Mohamed TM, Stanley PJ, Baudoin-Stanley F, Nadif R, Tommasi S, Pfeifer GP, Armesilla AL, Cartwright EJ, Neyses L,. 2009. Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation 120: 607-616.
30. Rohini A, Agrawal N, Koyani CN, Singh R,. 2010. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 61: 269-280.
31. Rose BA, Force T, Wang Y,. 2010. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev 90: 1507-1546.
32. Sanz L, Diaz-Meco MT, Nakano H, Moscat J,. 2000. The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 19: 1576-1586.
33. Schuh A, Liehn EA, Sasse A, Hristov M, Sobota R, Kelm M, Merx MW, Weber C,. 2008. Transplantation of endothelial progenitor cells improves neovascularization and left ventricular function after myocardial infarction in a rat model. Basic Res Cardiol 103: 69-77.
34. Shen DF, Tang QZ, Yan L, Zhang Y, Zhu LH, Wang L, Liu C, Bian ZY, Li H,. 2010. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Br J Pharmacol 159: 970-981.
35. Shirakata M, Imadome KI, Okazaki K, Hirai K,. 2001. Activation of TRAF5 and TRAF6 signal cascades negatively regulates the latent replication origin of Epstein-Barr virus through p38 mitogen-activated protein kinase. J Virol 75: 5059-5068.
36. Swynghedauw B, Delcayre C, Samuel JL, Mebazaa A, Cohen-Solal A,. 2010. Molecular mechanisms in evolutionary cardiology failure. Ann NY Acad Sci 1188: 58-67.
37. Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, Hashimoto H, Mak TW, Yagita H, Okumura K, Yeh WC, Nakano H,. 2001. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem 276: 36530-36534.
38. Tang ED, Wang CY,. 2010. TRAF5 is a downstream target of MAVS in antiviral innate immune signaling. PLoS ONE 5: e9172.
39. Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, Lan J, Zhuang GQ, Ma WZ, Wang W,. 2009. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med (Berl) 87: 249-260.
40. Xu YJ, Chapman D, Dixon IM, Sethi R, Guo X, Dhalla NS,. 2004. Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation. J Cell Mol Med 8: 85-92.
41. Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L, Bergmann MW,. 2009. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res 84: 416-424.